Ghost Tree Capital »

Travere Therapeutics shares owned by Ghost Tree Capital

Quarter-by-quarter ownership of Travere Therapeutics (TVTX) shares owned by Ghost Tree Capital from 13F filings

Historical chart of Ghost Tree Capital investment in Travere Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Travere Therapeutics held by Ghost Tree Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Travere Therapeutics by Ghost Tree Capital

Quarter filed Position value Share count Share price at filing
2023-09-30 $1.3M 150k 8.94
2020-12-31 $13M 475k 27.25

More positions owned by Ghost Tree Capital

Moonlake Immunotherapeutics Class A Ord (MLTX)
Sarepta Therapeutics (SRPT)
Spdr Ser Tr S&p Biotech Call Option (XBI)
Akero Therapeutics (AKRO)
Krystal Biotech (KRYS)
Madrigal Pharmaceuticals (MDGL)
Tg Therapeutics (TGTX)
Immunovant (IMVT)
Ascendis Pharma A/s Sponsored Adr (ASND)
Axsome Therapeutics (AXSM)
Alpine Immune Sciences (ALPN)
Syndax Pharmaceuticals (SNDX)
Vaxcyte (PCVX)
Tarsus Pharmaceuticals (TARS)
Apellis Pharmaceuticals Call Option (APLS)

View all positions for Ghost Tree Capital

Top funds holding Travere Therapeutics

Vanguard Group
Deutsche Bank Aktiengesellschaft
Kynam Capital Management
Jacobs Levy Equity Management
D. E. Shaw & Co
Bank of America Corporation
Goldman Sachs Group
Millennium Management
Emerald Advisers
Avidity Partners Management
Emerald Mutual Fund Advisers, Trust
Schonfeld Strategic Advisors
Barclays
Healthcare Of Ontario Pension Plan Trust Fund
Two Sigma Advisers

View all funds holding Travere Therapeutics